?Effect of Tocilizumab in Reducing Mortality and Need for Invasive Ventilation in a COVID-19 Infected Patients?
Coronavirus disease 2019 has claimed the lives of almost 2.5 million people, yet no viable therapy or care has yet been established. To learn more about Tocilizumab treatment for COVID-19 patients, studies were conducted.
The 2019 Coronavirus disease outbreak has created havoc and posed a significant epidemiological, diagnostic, and therapeutic challenge. The availability of vaccines has reduced the number of serious cases daily, but it hasn't reduced the need for appropriate treatment. The second wave hit the country in a big way and claimed lives in big numbers. Researchers are still looking for a viable treatment using medications that have been shown to help with other diseases. From the clinician’s side treatment angles have changed as time has elapsed. The experience has grown and we have a much better understanding of the disease in to remdesivir, low molecular weight Heparin, and Dexamethasone were the key recommendations initially. However, because the pathophysiology of COVID-19 is complex, treatment should involve suppression of the pro inflammatory cytokine in addition to antiviral action and coagulopathy treatment.
Tocilizumab, a recombinant anti IL6 receptor monoclonal antibody, has been approved for use for cytokine release syndrome due to COVID-19.
Recently, an antibody cocktail drug which is a combination of Casirivimab and Imdevimab has got approval by FDA and is available in the market now which has shown positive outcomes in infected patients. Another drug Sotrivimab which is a new COVID monoclonal antibody has been released by FDA as emergency use authorization.